Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...
1d
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer won its fight to buy obesity-drug maker Metsera, with an extra $1.7 billion and a little help from the Trump administration. Pfizer Inc. pulled off a comeback win, beating out Danish drug giant ...
You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating ...
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...
Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted ...
Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker ...
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed r ...
The clinical trials report on Hemophilia A highlights opportunities in optimizing trial locations, enhancing cost-efficiency, and strategizing investments by offering insights into trial distributions ...
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...
Investors in Pfizer Inc (Symbol: PFE) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback